GC 4419

Drug Profile

GC 4419

Alternative Names: GC-4419

Latest Information Update: 01 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galera Therapeutics
  • Class Antifibrotics; Antineoplastics; Chemoprotectants; Small molecules
  • Mechanism of Action Antioxidants; Superoxide dismutase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stomatitis
  • Phase I/II Head and neck cancer
  • Preclinical Cancer
  • No development reported Fibrosis

Most Recent Events

  • 31 Jul 2017 GC 4419 receives a Promising Innovative Medicines designation by the Medicines and Healthcare Products Regulatory Agency for Stomatitis (in head and neck cancer patients) in United Kingdom
  • 19 Jun 2017 Galera Therapeutics plans a phase I trial in Healthy volunteers in Australia (IV) (NCT03194139)
  • 15 Jun 2017 Preclinical development in Cancer is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top